Loading...
•
Dec 31, 2025
Akebia Q4 2025 Earnings Report
Akebia reported strong fourth quarter 2025 revenue growth driven by Vafseo launch and higher Auryxia sales, while narrowing its net loss year-over-year.
Key Takeaways
Total Q4 2025 revenue increased to 57620000, supported by 54300000 in net product revenue including 6200000 from Vafseo, while net loss improved to 12244000 compared to 22804000 in the prior year period.
Total revenue rose to 57620000 from 46497000 year-over-year.
Vafseo generated 6200000 in Q4 net product revenue in its first year of launch.
Auryxia net product revenue increased to 48100000 from 44400000 in Q4 2024.
Net loss narrowed to 12244000 compared to 22804000 in the prior year quarter.
Revenue by Segment
Forward Guidance
Akebia expects significant Vafseo revenue growth in 2026 driven by expanded access at dialysis organizations, new patient starts, and improved adherence, while anticipating Auryxia revenues to decline due to expanding generic competition.
Positive Outlook
- Expect significant Vafseo revenue growth in 2026.
- Expanded access to Vafseo therapy at dialysis organizations.
- Improved patient adherence rates supported by observed dosing protocols.
- Goal to establish Vafseo as standard of care for anemia due to CKD in dialysis patients.
- Existing cash resources expected to fund operations for at least two years.
Challenges Ahead
- Auryxia revenues expected to decrease in 2026 due to expanded generic competition.
- Patient demand declined approximately 1000000 sequentially in Q4.
- Fewer patient starts in Q4 impacted demand.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...